Page 17 - Hal Barron News Today

The FDA has issued an emergency use authorization for the monoclonal antibody sotrovimab to treat mild-to-moderate COVID-19 in patients at risk for progressing to severe disease, according to a press release. The emergency use authorization — now the third for a monoclonal antibody in the treatment of COVID-19 — is specifically for adults and children aged 12 years and older who weigh

Secretive hedge fund Elliott Management is understood to have phoned major GSK investors to discuss whether Emma Walmsley is the right choice to lead the FTSE 100 firm.

GSK, Vir’s COVID-19 mAb scores FDA emergency use approval Interim phase 3 trial results found sotrovimab reduced the risk of hospitalisation or death by 85% compared to placebo GlaxoSmithKline (GSK) and Vir Biotech’s COVID-19 monoclonal antibody (mAb) sotrovimab has been granted an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA). The EUA clears sotrovimab – previously known as VIR-7831 – for the treatment of mild-to-moderate COVID-19 in high-risk adults...

Sotrovimab will be available for appropriate patients diagnosed with COVID-19 in the US in the coming weeks and discussions with global regulators regarding authorisations in additional countries continue to advance, said GSK

US regulator authorises GSK and Virs sotrovimab for Covid treatment | Financial News

Read more about GSK says it aims to bring FDA-approved antibody therapy to India for Covid on Business Standard. Treatment with Sotrovimab resulted in an 85 per cent reduction in the risk of hospitalization, says company.

Subscription Notification We have noticed that there is an issue with your subscription billing details. Please update your billing details here Please update your billing information The subscription details associated with this account need to be updated. Please update your billing details here to continue enjoying your subscription. Your subscription will end shortly Please update your billing details here to continue enjoying your access to the most informative and considered journalism in ...

Sir John Bell fears UK risks talent exodus after AstraZeneca boss suffers shareholder revolt over pay

GSK moves to make up ground in vaccine race Company is talking to governments about creating vaccine manufacturing facilities about 4 hours ago   GlaxoSmithKline is banking that it can come back from behind in the race for a Covid-19 vaccine and play an important role preparing for new pandemics after releasing positive trial data. The vaccine maker is talking to governments including the UK about creating vaccine manufacturing facilities on their home turf, and is investing heavily in mRNA, ...

GSK moves into the vaccine race GlaxoSmithKline says it can backtrack on the Covid-19 vaccine and play an important role in preparing new pandemics after testing positive data. The vaccine maker is talking to internal governments in the UK about creating vaccine manufacturing facilities in their homes, and is investing heavily in mRNA, behind the successful plans of BioNTech / Pfizer and Moderna. GSK has not helped last year to any generation of Covid-19 vaccines his French partner Sanofi it h...